Dr. Jianguo Ma received both of his B.Sc. degree in chemistry (1988) and M.Sc. degree in synthetic organic chemistry (1991) from Lanzhou University. He was then awarded his Ph.D degree in 2001 in synthetic organic chemistry from University of Montreal under the supervision of Professor Stephen Hanessian. After two years’ postdoctoral research at Harvard University with Professor Yoshito Kishi, he then began his career in pharmaceutical industry and held various senior scientific positions at Memory pharmaceutical, Sepracor/Sunovion and AstraZeneca where he made key contributions to many medicinal chemistry programs in CNS (Alzheimer’s disease, Depression) and Oncology (Raf/MEK dual kinase inhibitors and Antibody-Drug Conjugates, ADC) as well as process chemistry programs. In 2012, he joined Asymchem and had been VP of R&D before he took the CTO (Chief technology Officer) position with Porton in 2014. After three years with Porton, he then joined Shanghai Medicilon as the VP of Chemistry and head of CDMO business.
Shanghai Medicilon Inc.